| Not Yet Recruiting | Clonal Hematopoiesis of Immunological Significance NCT05969821 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia NCT07033598 | Theradex | Phase 2 |
| Active Not Recruiting | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic NCT05883956 | Otsuka Australia Pharmaceutical Pty Ltd | Phase 3 |
| Active Not Recruiting | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are NCT05201066 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and NCT05218902 | Bristol-Myers Squibb | — |
| Withdrawn | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher NCT04264806 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or NCT04266301 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems NCT03814005 | Takeda | Phase 1 |
| Terminated | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome NCT03175978 | IGF Oncology, LLC | Phase 1 / Phase 2 |
| Completed | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Hi NCT03268954 | Takeda | Phase 3 |
| Unknown | A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) NCT03040401 | Vastra Gotaland Region | Phase 1 / Phase 2 |
| Completed | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs NCT02907359 | Astex Pharmaceuticals, Inc. | Phase 3 |
| Completed | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia NCT02807272 | Kura Oncology, Inc. | Phase 2 |
| Terminated | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes NCT02841540 | Hemavant Sciences GmbH | Phase 1 |
| Completed | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants NCT02610777 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT NCT02472691 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238 | University Health Network, Toronto | — |
| Completed | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelo NCT02201329 | Boehringer Ingelheim | Phase 1 |
| Terminated | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML NCT01957644 | Boehringer Ingelheim | Phase 1 |
| Completed | Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Pa NCT02085798 | Celgene | — |
| Completed | An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in NCT02891551 | Celgene | — |
| Completed | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine NCT01519011 | Celgene | Phase 1 |
| Completed | Korean Post-marketing Surveillance for Sprycel® NCT01464047 | Bristol-Myers Squibb | — |
| Completed | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Mul NCT00761722 | Celgene | Phase 1 |
| Completed | Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS NCT00744536 | Sunnybrook Health Sciences Centre | Phase 2 |
| Terminated | Sorafenib in Myelodysplastic Syndrome NCT00510289 | Duke University | Phase 2 |
| Completed | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) NCT00255346 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomono NCT00109538 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |